Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on [...]
My recent Letter to the Editor of the New York Times in response to the Op-Ed piece decrying the cost of cancer treatments: Your recent editorial about the high cost of cancer drugs missed a number of very significant points which must be considered. Yes, newly developed cancer drugs are expensive, but when treatments like [...]
We dodged a bullet… for now! I’m pleased to report that the House just approved the FY12 DoD Appropriations Bill by a vote of 331-83. No amendments were offered to reduce or eliminate CDMRP (the Department of Defense Medical Research Program) funding. At this time we have managed to maintain the funding for the Prostate [...]
Yesterday there was an amendment passed on the House floor to restore the Prostate Cancer Research Program's 2012 funding to $80 million. The Department of Defense (DoD) Appropriations Bill (H.R. 2219) originally was slated to allocate only $64 million to the Prostate Cancer Research Program (PCRP), a 20% reduction from last year’s funding. Restoring these [...]
Things are looking up for our European readers. It must be frustrating for people outside of the United States to read this blog and learn about the many advances we now have in the US which are not available to them. The good news is that Sanofi has just launched Jevtana (cabazitaxel) in the UK [...]